What are the contraindications to beta‑3 adrenergic agonist therapy (e.g., mirabegron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Contraindications to Beta-3 Adrenergic Agonists

The primary contraindication to beta-3 adrenergic agonist therapy (mirabegron) is severe uncontrolled hypertension, defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg in adults, or blood pressure above the 99th percentile plus 5 mm Hg for age, sex, and stature in pediatric patients. 1, 2

Absolute Contraindications

Hypersensitivity

  • Known hypersensitivity reactions to mirabegron or any inactive ingredients of the formulation 2

Severe Uncontrolled Hypertension

  • Adults: Systolic BP ≥180 mm Hg and/or diastolic BP ≥110 mm Hg 1, 2
  • Pediatric patients (≥3 years): BP above 99th percentile plus 5 mm Hg for age, sex, and stature 2

This is the most clinically significant contraindication based on the most recent European Association of Urology guidelines (2023) and FDA labeling, as mirabegron can cause dose-dependent increases in blood pressure 1.

Relative Contraindications and Cautions

Cardiovascular Considerations

While not absolute contraindications, mirabegron should be used with extreme caution in:

  • Patients with pre-existing hypertension requiring periodic blood pressure monitoring 1, 2
  • The drug causes mean increases in systolic/diastolic BP of approximately 0.5-1 mm Hg in OAB patients, though healthy volunteers showed increases up to 3.5/1.5 mm Hg 2
  • Blood pressure increases may be larger in children (3 to <12 years) than in adolescents 2

Bladder Outlet Obstruction

  • Administer with caution in patients with clinically significant bladder outlet obstruction
  • Monitor for signs and symptoms of urinary retention 2
  • A controlled safety study did not demonstrate increased urinary retention, but vigilance is warranted 2

Concurrent Antimuscarinic Use

  • Use caution when combining with muscarinic antagonist medications for OAB due to potential additive risk of urinary retention 2

Dosing Adjustments (Not Contraindications)

Renal Impairment

  • Severe renal impairment (eGFR 15-29 mL/min/1.73 m²): Maximum dose 25 mg daily 2
  • End-stage renal disease (eGFR <15 mL/min/1.73 m²): Not recommended 2

Hepatic Impairment

  • Moderate hepatic impairment (Child-Pugh Class B): Maximum dose 25 mg daily 2
  • Severe hepatic impairment (Child-Pugh Class C): Not recommended 2

Important Safety Considerations

Angioedema Risk

While not a contraindication, angioedema of the face, lips, tongue, and/or larynx has been reported with mirabegron, sometimes after the first dose. This may be life-threatening if upper airway swelling occurs 2.

Advantages Over Antimuscarinics

The 2023 EAU guidelines note that mirabegron is well tolerated in elderly patients and those with multiple comorbidities, with fewer contraindications than many alternative therapies 1. The most frequent adverse effects are hypertension, UTIs, headache, and nasopharyngitis—notably lacking the anticholinergic burden of antimuscarinic agents 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.